275 related articles for article (PubMed ID: 27209586)
21. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent.
Dorinsky P; DePetrillo P; Siddiqui S; Maes A; Reisner C
Pulm Pharmacol Ther; 2018 Aug; 51():18-25. PubMed ID: 29763659
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
24. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
[TBL] [Abstract][Full Text] [Related]
27. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
[TBL] [Abstract][Full Text] [Related]
28. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
29. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
[TBL] [Abstract][Full Text] [Related]
30. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent.
Chawes BL; Govoni M; Kreiner-Møller E; Vissing NH; Poorisrisak P; Mortensen L; Nilsson E; Bisgaard A; Dossing A; Deleuran M; Skytt NL; Samandari N; Piccinno A; Sergio F; Ciurlia G; Poli G; Acerbi D; Singh D; Bisgaard H
Respir Med; 2014 Aug; 108(8):1108-16. PubMed ID: 24993817
[TBL] [Abstract][Full Text] [Related]
31. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination.
Bousquet J; Poli G; Acerbi D; Monno R; Ramael S; Nollevaux F
Clin Pharmacokinet; 2009; 48(6):347-58. PubMed ID: 19650674
[TBL] [Abstract][Full Text] [Related]
32. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
[TBL] [Abstract][Full Text] [Related]
34. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
[TBL] [Abstract][Full Text] [Related]
35. Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.
Usmani OS; Baldi S; Warren S; Panni I; Girardello L; Rony F; Taylor G; DeBacker W; Georges G
J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):179-185. PubMed ID: 35128939
[No Abstract] [Full Text] [Related]
36. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
37. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122
[TBL] [Abstract][Full Text] [Related]
38. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol pMDIs in asthmatic children.
Chawes BL; Piccinno A; Kreiner-Møller E; Vissing NH; Poorisrisak P; Mortensen L; Nilson E; Bisgaard A; Dossing A; Deleuran M; Skytt NL; Samandari N; Sergio F; Ciurlia G; Poli G; Acerbi D; Bisgaard H
Br J Clin Pharmacol; 2013 Apr; 75(4):1081-8. PubMed ID: 22978252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]